Golden Recursion Inc. logoGolden Recursion Inc. logo
Advanced Search
Arrakis Therapeutics (Company)

Arrakis Therapeutics (Company)

Arrakis is developing RNA-targeted small molecule (rSM) therapies to millions of patients.

Arrakis Therapeutics is a biopharmaceutical company that is pioneering the discovery of a new class of medicines which targets RNA-targeted small molecules. The company’s platforms, TRYST™ and PEARL-seq™, identify new RNA targets and drug candidates for treating diseases that have not been addressed by today’s medicines.

Arrakis is developing a proprietary pipeline of RNA-targeted small molecules that focuses on neurologic diseases, cancer, and rare genetic diseases.

Arrakis was launched in 2015 by Alan Walts, Ph.D., Russell Petter, Ph.D., Henri Termeer and Raj Parekh, Ph.D. with the vision to develop a proprietary, transformational discovery platform that identifies small-molecule drugs that work on disease-causing RNA.

The company was established with seed funding that was provided by Advent Life Sciences and Henri Termeer. The company puts together scientific leaders in RNA structure, chemistry and biology, together with a management team and the backing of life sciences investors.


April 18, 2019
Arrakis Therapeutics raises a $75,000,000 series B round.
April 2019
Arrakis Therapeutics raises a $75,000,000 series B round from Canaan Partners, Celgene, Google Ventures, HBM Healthcare Investments AG, Nextech Invest, Omega Funds and Osage University Partners.
February 27, 2017
Arrakis Therapeutics raises a $38,000,000 series A round.
February 2017
Arrakis Therapeutics raises a $38,000,000 series A round from Advent Life Sciences, Canaan Partners, Celgene, Henri Termeer, Osage University Partners and Pfizer.

Funding rounds


Further Resources



May 5, 2021
Affinivax, Inc. ("Affinivax"), a clinical stage biopharmaceutical company pioneering the development of a novel class of vaccines with its MAPSTM (Multiple Antigen Presenting System) platform , today announced that Elizabeth Radcliffe has joined the company as Chief Financial Officer.
November 19, 2020
Arrakis Therapeutics , a biopharmaceutical company pioneering the discovery of a new class of small molecule medicines that directly target RNA, today announced that Patrizio Renzetti has joined the company as Vice President, Human Resources. Patrizio is an experienced human resources leader with broad expertise at dynamic high-growth companies, both large and small, including Agios Pharmaceuticals, Lilly, and Procter &a
Golden logo
By using this site, you agree to our Terms & Conditions.